cse: ABRT

Corporate Presentation
Credible

Proven

Single dose, generally safe and high efficacy,
proven in academic research

Scalabe

Huge Immediate Need

Cancer Related Mental Distress: 15 million
Mental Health Sufferers: ~792 million

Focu

Key Milestones for 2023

Pharmacokinetic Study (Phase 1) completion
Q3 2023

Faster

Rapid Access

Accelerated clinical development strategy
(Real World Evidence)

Website

Latest Press Release

Albert Labs Welcomes Dr. Shabir Hasham to Board of Directors

Read more

By completing this form you agree to our privacy policy. You will be sent corporate updates and further details including how to invest in Albert Labs.